FRNM - Latest News
Freenome, Inc. (FRNM), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $114.9M. Beta to the broader market is 0.35.
The article list below shows the most recent FRNM headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent FRNM Headlines
FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test
globenewswire.com - Aug 12, 2026
BRISBANE, Calif. , Aug.
FDA approves Freenome's blood test for colorectal cancer screening
reuters.com - Jul 27, 2026
The U. S.
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
globenewswire.com - Jul 27, 2026
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and Amer
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
globenewswire.com - Jul 20, 2026
– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to F
How News Affects FRNM Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track FRNM's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked FRNM news questions
- What is the latest FRNM news headline?
- The most recent FRNM headline (Aug 12, 2026) is "FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the FRNM news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What FRNM news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual FRNM options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.